Navigation Links
Select Medical Holdings Corporation Announces Results for Third Quarter Ended September 30, 2009
Date:11/5/2009

9,614 admissions in the same quarter, prior year. Adjusted EBITDA for the segment increased 31.0% to $64.4 million compared to $49.1 million for the same quarter, prior year. The Adjusted EBITDA margin for the segment was 17.1% for the third quarter of 2009, compared to 13.7% for the same quarter, prior year. The Adjusted EBITDA margin for the hospitals opened or acquired as of January 1, 2008 and operated by Select throughout both periods was 18.1% for the third quarter of 2009, compared to 16.0% for the same quarter, prior year.

For the nine months ended September 30, 2009, net operating revenues for all of Select's hospitals increased 4.7% to $1,156.4 million compared to $1,104.7 million for the same period, prior year. Total patient days for the nine months ended September 30, 2009 were 757,487, admissions were 31,775 and net revenue per patient day was $1,500. This compares to 756,093 days, 30,891 admissions and net revenue per patient day of $1,434 for the same period, prior year. For the hospitals opened or acquired as of January 1, 2008 and operated by Select throughout both periods, patient days for the nine months ended September 30, 2009 were 705,692 and admissions were 29,570, compared to 728,733 days and 29,794 admissions in the same period, prior year. Adjusted EBITDA for the segment for the nine months ended September 30, 2009 increased 26.6% to $212.1 million compared to $167.6 million for the same period, prior year. The Adjusted EBITDA margin for the segment for the nine months ended September 30, 2009 was 18.3%, compared to 15.2% for the same period, prior year. The Adjusted EBITDA margin for the hospitals opened or acquired as of January 1, 2008 and operated by Select throughout both periods was 19.8% for the nine months ended September 30, 2009, compared to 17.3% for the same period, prior year.

Outpatient Rehabilitation

At September 30, 2009, Select operated 947 outpatient clinics. This compares to
'/>"/>

SOURCE Select Medical Holdings Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related medicine news :

1. Brooke Franchise Corporation Announces Selected July Results
2. Novel 3-D cell culture model shows selective tumour uptake of nanoparticles
3. Corbett Selected to Host the Only Midwest Global Awards Judging Competition
4. Draxis Health selected by Johnson and Johnson Consumer Companies, Inc. for major contract manufacturing relationship
5. Crdentia Selected by High Rock Raceway to Provide Healthcare Staffing Services
6. Mindray Selects Actel Low-Power Flash FPGAs for Demanding Medical Equipment Applications
7. Purdue Pharma Selects Systech to Provide Sustainable Infrastructure for Serialization
8. Harvard Researchers Select S.C. BlueCross for National Honor
9. Loma Linda University Medical Center Selects Beryl to Manage Call Center Interactions for Womens Services Programs and Departments
10. Fry Construction Selected for High-Profile Medical Imaging Project
11. Meth Project Advertisements Selected for National Prevention Campaign

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...atory consulting firm Emergo Group recently survey...ors and industry service providers about the state...nd their outlook for 2010. , ...bal medical device regulatory consulting firm Em...nd IVD manufacturers, distributors and industry se...
(Date:11/24/2009)... be coupled with Stem Cell Therapy. , ...09 -- Entest Biomedical, Inc. (OTCBB: ENTB) anno...ufacturer of lasers regarding the development of a...Entest and used in conjunction with several stem c... These therapies are aimed at increasing efficacy ...
(Date:11/24/2009)...will be offering a free online seminar (webinar) o...d certified ophthalmologist and pioneer in LASIK s... , (Vocus) November 23, 20...nar on LASIK Vision Correction – which can b...is free to anyone attending., , ,The webinar is pr...
(Date:11/24/2009)...-USFarms,Inc.,(PinkSheets:USFM)adiversifiedsupplie...nounceithasreceivedformalcertificationapprovalbyth...M)Juiceproduct. ,, YanSkwara,CEOofUSFarms,Inc.s...edthecertificationprocesswiththeAmericanVegetarian...goaloftheAVAistoprovideawidelyrecognizedcertificat...
(Date:11/24/2009)...CountyHeathcare(LCH)isasmallhealthsystemontherugge...munities,employingmorethan1,200fullandpart-timepeo...uccessfulbackup,you,renotdoingyourjob,"saysBrooksB...hecasewithmanyhospitalsinMaine,budgetsareextremely...rotecthismissioncriticalsystems.Hedrewupaplan,went...
Breaking Medicine News(10 mins):Health News:Medical Device Industry Positive About 2010 – Survey 2Health News:Entest Biomedical Enters into Discussions with Laser Manufacturer to Develop Proprietary Photoceutical Device for COPD Treatment 2Health News:Free LASIK Surgery Webinar 2Health News:Free LASIK Surgery Webinar 3Health News:Free LASIK Surgery Webinar 4Health News:US Farms, Inc. Receives American Vegetarian Association Certification Approval for Aloe365(TM) Juice Product 2Health News:Replay 4 Customer Takes Risk, Fights for Budget to Protect Information Systems 2
... Delhi Cabinet today cleared the business model fo...ary Sciences (ILBS) being set up in the capital. /...eeting chaired by Chief Minister Sheila Dikshit wo...edical equipment would be borne by Delhi Governmen...
... Zolpidem is usually used to treat insomnia. T...ied for a period of six months by South African re...eveal that they are in a condition where keeping e... Zolpidem was given to the patients every morn...
... There appears to be a ray of hope for men, who ar...on with no remedy from available treatment measure...where the animal’s very own penile cells were used...s were introduced with a graft made from manufactu...
... Scott and Nicola Smith of Leicester parents of si...ffering from the incurable disorder Adrenoleukodys...ading to hear came true yesterday with reports ind...e nearly always male who lose sight, hearing, and ...
... The results of a new study shows that people with...to develop heart failure in middle age, the result...ome means a cluster of conditions, including obesi...disease, stroke and diabetes. A team of Swedish re...
... Researchers from the University of Florida announ...hickens with a disease that otherwise would have l...e researchers hope that the gene therapy may one d... the research, which delayed the onset of blindnes...
Other Medicine News:Health News:A Mother Passes On A Rare, Terminal Brain Disease To Her Three Children 2Health News:Gene Therapy May Help Restore Sight In Congenital blindness 2
(Date:11/24/2009)...v.24/PRNewswire/--AFOXThanksgivingDaytelevisionspe....S.remindsviewersthattheholidaysareatimetobegratef...rallthosewhofightthatbattleeachdayassurvivors,care...hehistoricreturntotheiceofcancersurvivorsScottHami...on-JohnandDavidFosterwhowillperform"HopeisAlwaysHe...
(Date:11/23/2009)...,Nov.23/PRNewswire-USNewswire/--FebeDurango-Rueda,...oparticipatinginaschemetodefraudtheExport-ImportBa...announcedAssistantAttorneyGeneraloftheCriminalDivi....GratacosoftheEx-ImBank,OfficeoftheInspectorGenera...obertsinU.S.DistrictCourtinWashingtontoaone-countc...
(Date:11/23/2009)...a.,Nov.23/PRNewswire-FirstCall/--Immucor,Inc.(Nasd...ment-reagentsystemstothebloodtransfusionindustry,t...Jaffray21stAnnualHealthCareConferenceinNewYork,NYw...TheCompany,spresentationisscheduledforTuesday,Dece...ntationwillbeavailablethroughthe"AboutUs--Investor...
Breaking Medicine Technology:FOX Thanksgiving Day Special 'Kaleidoscope' Unites Cancer Survivors on Ice and in Song to Celebrate Survivorship 2FOX Thanksgiving Day Special 'Kaleidoscope' Unites Cancer Survivors on Ice and in Song to Celebrate Survivorship 3Colombian National Pleads Guilty to Role in Defrauding the Export-Import Bank of the United States of More Than $1 Million 2Palkion Selects Novel Oral Development Candidate for the Treatment of Anemia 12813 1Palkion Selects Novel Oral Development Candidate for the Treatment of Anemia 12813 2Palkion Selects Novel Oral Development Candidate for the Treatment of Anemia 12813 3Video 3A New Online Film Introduces Longevinex Advantage 28TM 29 The First Resveratrol Based Dietary Supplement to Address Both Cellular and Connec 50244 1Video 3A New Online Film Introduces Longevinex Advantage 28TM 29 The First Resveratrol Based Dietary Supplement to Address Both Cellular and Connec 50244 2Vantia Therapeutics Lead Candidate VA106483 Demonstrates Positive Anti diuretic Effect in Phase IIa Trial in Nocturia 4662 1Vantia Therapeutics Lead Candidate VA106483 Demonstrates Positive Anti diuretic Effect in Phase IIa Trial in Nocturia 4662 2Vantia Therapeutics Lead Candidate VA106483 Demonstrates Positive Anti diuretic Effect in Phase IIa Trial in Nocturia 4662 3
...SAN MATEO, Calif., Oct. 3 Anthera Pharmaceuticals...developing,anti-inflammatory therapeutics for chro...y the completion of enrollment and patient dosing ...d, A-002 for stable coronary,artery disease. Data ...f,the year. "We are pleased with the rapid enroll...
...NEW YORK, Oct. 2 ImClone Systems Incorporated,(Na...SE: BMY ) today announced,that the U.S. Food and ...o,the ERBITUX(R) (Cetuximab) product labeling to i...epidermal growth factor inhibitor,(EGFR)-expressin...er,failure of both irinotecan- and oxaliplatin-bas...
Other Medicine Technology:Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease 2Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease 3Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer 2Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer 3Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer 4Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer 5Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer 6Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer 7
TPS-TL Spinal Spacer
...esorbable, osteoconductive matrix consisting of hy...ared for use in oral maxillofacial procedures as a...g Pro Osteon 200R has been FDA indicated as a bone...h bone during the healing process. Its interconnec...
O-arm Complete Multidimensional Surgical Imaging
Merlin Patient Care System
Medicine Products: